[Brief Introduction of Seminar]

Korea has been intended to advance a cutting-edge initiative focused on the R&D of personalized cancer vaccines (PCV). This national project (ARPA-H PAVE) integrates genomic profiling, AI-driven neoantigen prediction, and mRNA vaccine technology to create individualized treatments tailored to each patient’s tumor profile. The program represents a convergence of strengths in biotech innovation, clinical research, and AI infrastructure that have been growing in Korea. Its goal is to deliver safer, more effective cancer immunotherapies fully personalized.

[Brief Introduction of Speaker]​

​Hun Jung (MD, PhD) worked as a surgeon at Seoul St. Mary’s Hospital and Samsung Medical Center. From 2011 to 2017, he worked for a MSD, and he worked at Samsung Bioepis from 2017 to 2018. In 2018, he founded Aston Sci. and has since been developing therapeutic cancer vaccines.​

[Brief Introduction of Seminar]

Introducing the story of UMTR Co., Ltd., which is start-up in Korea to against legacy players who has a long history based on excellent technology. To become one of the top 5 global bioprocess companies based on the goal of localization in the bioprocess field.

[Brief Introduction of Speaker]​

​CEO Sungryul Park received his master's and Ph.D degree in the membrane field and worked several years. After that, he supported the industrial technology R&D policy and realized the need for domestic production and global advancement of bioprocess especially the membrane field, and founded the company, which has continued to this day.​

[Brief Introduction of Seminar]

This presentation addresses supply chain strengthening strategies through the localization of biopharmaceutical raw materials. Led by Korea Conformity Laboratories (KCL), this project aims to secure global competitiveness in the bio-industry by establishing value chains between supply and demand companies. The presentation will introduce comprehensive support systems including forward-backward integration projects for raw material self-sufficiency across cultivation to purification processes, performance evaluation and technical education programs, and domestic/international exhibition support, proposing ways to strengthen the bio-industry ecosystem.

[Brief Introduction of Speaker]​

​Korea Conformity Laboratories (KCL), established in 2010, is Korea's largest comprehensive testing and certification institution. As an affiliated organization of the Korean Agency for Technology and Standards under the Ministry of Trade, Industry and Energy, KCL conducts testing, inspection, and certification services across diverse fields from construction materials to bio-healthcare. In the bio-industry sector, KCL is designated as a GLP-compliant institution and medical device testing laboratory by the Ministry of Food and Drug Safety, contributing to strengthening Korea's bio-industry ecosystem through safety evaluation of pharmaceuticals, medical devices, and cosmetics, and supporting commercialization of biopharmaceutical raw materials.​

[Brief Introduction of Seminar]

The core strategy for localization of bioprocess in Korea centers on three key factors. First, differentiated technology development and continuous R&D investment are essential for global competitiveness. Second, collaboration with demand companies and product validation are needed to build trust and drive actual purchases of domestic products. Third, strong support from the government and local authorities—through policy, funding, specialized industrial zones, and regulatory improvements—is crucial. When these three elements work together, Korea’s bio industry can achieve self-reliance and enhanced global competitiveness.

[Brief Introduction of Speaker]​

​Dr. Su-Lim Choi is a Amicogen's Head of R&D.At AMICOGEN, Dr. Choi is focusing on localizing the production of biotech materials, components, and equipment and on developing and selling essential biopharmaceutical materials such as media, enzymes and resins.​

[Brief Introduction of Seminar]

Women’s health is a dynamic process shaped by biological, hormonal, and social factors. Recognizing hormonal changes at each stage of life allows for better care and prevention, ensuring improved quality of life during these sensitive phases. Saffr’Activ® is an excellent active ingredient, backed by strong scientific support, and has shown significant effects in reducing health issues related to hormonal changes during the fertile stage, pregnancy, perimenopause, menopause, and postmenopause.

​

Technical sales specialised in plants extracts and saffron​​ 

[Brief Introduction of Seminar]

BASF as global chemical company provides various chemicals. Synthetic vitamins are one of portfolios in BASF. We would like to take this opportunity to introduce BASF’s portfolio, including vitamins, designed to support brain, heart, and overall health, to the Korean nutrition market.

​

[Brief Introduction of Speaker]

After completing Ph.D. in Pharmaceutical Science, Yuki Kobayashi joined BASF Japan Ltd. Nutrition& Health division.

She handles health ingredients and provides technical support and scientific information to contribute to people's health. 

[Brief Introduction of Seminar]

ILIAS Biologics has developed first-in-class anti-inflammatory exosome therapeutics targeting intracellular signaling pathways involved in immune and inflammatory responses. In this presentation, I will share our nonclinical findings and results from the Phase 1 clinical trial.

[Brief Introduction of Speaker]​

​Dr. Chulhee Choi, CEO of ILIAS Biologics, laid the foundation for the company by developing an exosome-based platform technology for the delivery of protein therapeutics. To date, he has published over 150 papers in leading scientific journals and holds more than 40 international patents. Prior to founding ILIAS Biologics, Dr. Choi served as a professor in the Department of Bio and Brain Engineering at KAIST for 17 years. He earned his M.D. and Ph.D. in Microbiology from Yonsei University College of Medicine and completed his residency in neurology at Severance Hospital, Yonsei University.​

[Brief Introduction of Seminar]

In the development of therapeutics using Extracellular Vesicles (EVs), two main approaches are widely recognized: utilizing EVs as drug delivery system (DDS) tools, and developing EVs themselves as therapeutic agents. Brexogen is taking the latter approach—developing EVs as therapeutics. By applying a preconditioning strategy, Brexogen modulates the cargo of naïve EVs to enhance their therapeutic functions and develop them into effective treatments. In this presentation, we will introduce Brexogen’s core technology and current development programs.

[Brief Introduction of Speaker]​

​The speaker is currently the Head of Development at Brexogen. He began his career as a formulation researcher at a domestic pharmaceutical company and has since worked at various pharmaceutical firms in roles related to drug development and business development. His experience includes the development of new drugs and products, as well as licensing in and out. He has also been involved in numerous U.S. IND submissions and management of clinical trials in the course of new drug development.​

[Brief Introduction of Seminar]

Stem cell-derived exosomes are emerging as a next-generation modality in the challenging field of neuroregeneration, where conventional single-target therapies have shown clear limitations. With their diverse therapeutic cargo, inherent targeting ability, and potential as delivery vehicles, they offer new possibilities for treating complex neurological conditions. In this presentation, we will share the development journey and clinical translation of SNE-101, designed to promote functional recovery in patients with acute ischemic stroke. As there are still no clear legal frameworks or detailed guidelines for exosome-based therapeutics, our team worked closely with regulatory authorities over an extended period to achieve Korea’s first Phase 1 IND approval for an exosome therapy. To support this, we established large-scale production and rigorous quality control systems to ensure safety and consistency, and demonstrated efficacy and safety in non-human primate models. We are now preparing for a first-in-human clinical trial in Korean stroke patients and envision expanding this platform to address unmet needs in neurodegenerative diseases, paving the way for new therapeutic options and industrial growth.

[Brief Introduction of Speaker]​

​She earned her Ph.D. from Yonsei University College of Medicine and has conducted research at the Department of Neurology and the Stem Cell Translational Research Institute at Samsung Medical Center, working on the development of stem cell therapies for various neurological diseases such as stroke and Moyamoya disease, as well as the development of therapeutics and processes using stem cell-derived exosomes. She is currently Chief Technology Officer (CTO) and Director of the Research Center at S&E Bio Co., Ltd., where she has focused on developing the SNE-101 therapy and recently led Korea’s first Phase 1 IND approval for an exosome treatment for patients with acute ischemic stroke. She is committed to presenting a new treatment paradigm for intractable neurological diseases through the clinical application of stem cells and exosomes.​